Market and Product Forecasts: Depression - Pipeline Set to Rejuvenate Saturated Market

Sep 20, 2011, 06:15 ET from Reportlinker

NEW YORK, Sept. 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Market and Product Forecasts: Depression - Pipeline set to rejuvenate saturated market

http://www.reportlinker.com/p0618135/Market-and-Product-Forecasts-Depression---Pipeline-set-to-rejuvenate-saturated-market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

New product launches across the seven major markets will expand the market out to 2020, reinforcing the depression market's status as one of the largest of the CNS disorders. Datamonitor expects the pipeline to forge a sizable market share - Valdoxan (agomelatine; Servier/Novartis) will become the highest-selling drug, while TC-5214 (Targacept/AstraZeneca) also possesses blockbuster potential. Access Datamonitor's patient-based depression market forecast in the seven major markets, with transparent methodology and clear assumptions. Evaluate a highly granular forecast with sales value and volume projections to 2020 at the country, class, product, and regimen level. Understand depression market dynamics, and which factors will lead to commercial success. Review the products Datamonitor forecasts to launch over the next ten years, and how each subsequent launch will shape the market. Datamonitor forecasts the seven major depression markets to grow to $14.0bn by 2020 at a compound annual growth rate of 2.5%. This steady growth is expected to come from uptake of new product launches and will offset increasing generic erosion of the market value. By 2020, sales of the leading depression drug classes, such as the SSRI antidepressants, SNRI antidepressants, and atypical antipsychotics are expected to decline. Conversely, sales of non-traditional antidepressants are projected to rise from $1.4bn in 2010 to $6.4bn in 2020. Sales of currently marketed products are forecast to decrease three-fold over 2010–20, as the saturation of the depression market with generics increases. Nevertheless, Datamonitor expects new pipeline drugs to capture a sizable share of the market, with predicted total sales of $5.9bn in 2020 equating to a market share of 41.9%. What degree of commercial success does Datamonitor forecast for key pipeline drugs? What will the overall depression market dynamics be over the next 10 years? How will sales of the major drug classes in depression evolve during the forecast period? Which of the seven major markets provides the greatest opportunity for growth? How will first-, second-, and third- brand dynamics change in the depression markets over the coming decade?

OVERVIEW

•Catalyst

•Summary

EXECUTIVE SUMMARY

•Strategic scoping and focus

•Datamonitor key findings

•Related reports

MARKET DEFINITION

•Market definition for this disease

•Forecast methodology and assumptions

- Methodology flow

- Patent expiries

- New product launches

MARKET OVERVIEW AND CONTEXT

•Current and future market dynamics overview

- Depression market set for steady expansion despite patent expiries

- Non-traditional antidepressants will provide growth as conventional classes decline

- High value lies in combination therapies for depression

- US market overview

- Japan market overview

- France market overview

- Germany market overview

- Italy market overview

- Spain market overview

- UK market overview

PRODUCT FORECASTS

•Product dynamics

- The pipeline will account for over 40% of the market value by 2020

•Valdoxan (agomelatine; Servier/Novartis)

- Forecast assumptions

- Valdoxan forecast 2010–20

•TC-5214 (Targacept/AstraZeneca)

- Forecast assumptions

- TC-5214 forecast 2010–20

•Lu AA21004 (Lundbeck/Takeda)

- Forecast assumptions

- Lu AA21004 forecast 2010–20

•Viibryd (vilazodone; Forest)

- Forecast assumptions

- Viibryd forecast 2010–20

•OPC-34712 (Otsuka)

- Forecast assumptions

- OPC-34712 forecast 2010–20

•Edivoxetine (LY2216684; Eli Lilly)

- Forecast assumptions

- Edivoxetine forecast 2010–20

•Levomilnacipran (F2695; Forest/Pierre Fabre)

- Forecast assumptions

- Levomilnacipran forecast 2010–20

•Vyvanse (lisdexamfetamine; Shire)

- Forecast assumptions

- Vyvanse forecast 2010–20

BIBLIOGRAPHY

•Journal papers

•Datamonitor reports

APPENDIX

•Contributing experts

•Conferences attended

•Forecast methodology

- Volume and value forecast methodology

- Price and compliance assumptions

- Physician sample breakdown

•Report methodology

TABLES

•Table: Summary of therapeutic classes in depression by Anatomical Therapeutic Chemical code, 2011

•Table: ICD-10 and DSM-IV codes for major depressive disorder

•Table: Patent expiry/generic launch dates for key brands in depression in the seven major markets, 2011

•Table: Estimated launch dates for key late-stage pipeline products and marketed brands in depression in the seven major market regions, 2010–20

•Table: Depression market sales value ($m) and volume (number of regimens) dynamics in the seven major markets, 2010–20

•Table: Depression class sales value ($m) and volume (number of regimens) dynamics in the seven major markets, 2010–20

•Table: Depression product sales in the US ($m), 2010–20

•Table: Depression product sales in Japan ($m), 2010–20

•Table: Depression product sales in France ($m), 2010–20

•Table: Depression product sales in Germany ($m), 2010–20

•Table: Depression product sales in Italy ($m), 2010–20

•Table: Depression product sales in Spain ($m), 2010–20

•Table: Depression product sales in the UK ($m), 2010–20

•Table: Depression product sales in the seven major markets ($m), 2010–20

•Table: Valdoxan (agomelatine; Servier/Novartis) sales forecast for depression in the seven major markets ($m), 2010–20

•Table: TC-5214 (Targacept/AstraZeneca) sales forecast for depression in the seven major markets ($m), 2010–20

•Table: Lu AA21004 (Lundbeck/Takeda) sales forecast for depression in the seven major markets ($m), 2010–20

•Table: Viibryd (vilazodone; Forest) sales forecast for depression in the seven major markets ($m), 2010–20

•Table: OPC-34712 (Otsuka) sales forecast for depression in the seven major markets ($m), 2010–20

•Table: Edivoxetine (LY2216684; Eli Lilly) sales forecast for depression in the seven major markets ($m), 2010–20

•Table: Levomilnacipran (Forest/Pierre Fabre) sales forecast for depression in the seven major markets ($m), 2010–20

•Table: Vyvanse (lisdexamfetamine; Shire) sales forecast for depression in the seven major markets ($m), 2010–20

•Table: Psychiatrists surveyed regarding major depressive disorder across the seven major markets, 2010

FIGURES

•Figure: Patient-based forecast methodology for depression, 2011

•Figure: Depression market sales value ($m) in the seven major markets, 2010–20

•Figure: Depression drug class sales in the seven major markets ($m), 2010–20

•Figure: Sales value of the depression market, by regimen ($m), 2010

•Figure: Depression product sales in the US ($m), 2010–20

•Figure: Depression product sales in Japan ($m), 2010–20

•Figure: Depression product sales in France ($m), 2010–20

•Figure: Depression product sales in Germany ($m), 2010–20

•Figure: Depression product sales in Italy ($m), 2010–20

•Figure: Depression product sales in Spain ($m), 2010–20

•Figure: Depression product sales in the UK ($m), 2010–20

•Figure: Depression product sales in the seven major markets ($m), 2010–20

•Figure: Valdoxan (agomelatine; Servier/Novartis) sales forecast for depression in the seven major markets ($m), 2010–20

•Figure: TC-5214 (Targacept/AstraZeneca) sales forecast for depression in the seven major markets ($m), 2010–20

•Figure: Lu AA21004 (Lundbeck/Takeda) sales forecast for depression in the seven major markets ($m), 2010–20

•Figure: Viibryd (vilazodone; Forest) sales forecast for depression in the seven major markets ($m), 2010–20

•Figure: OPC-34712 (Otsuka) sales forecast for depression in the seven major markets ($m), 2010–20

•Figure: Edivoxetine (LY2216684; Eli Lilly) sales forecast for depression in the seven major markets ($m), 2010–20

•Figure: Levomilnacipran (Forest/Pierre Fabre) sales forecast for depression in the seven major markets ($m), 2010–20

•Figure: Vyvanse (lisdexamfetamine; Shire) sales forecast for depression in the seven major markets ($m), 2010–20

Companies Mentioned

Hutchison 3G UK Limited

To order this report:

Pathology Industry: Market and Product Forecasts: Depression - Pipeline set to rejuvenate saturated market

Pathology Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com